FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1547840953> ?p ?o ?g. }

• W1547840953 endingPage "2024s" @default.
• W1547840953 startingPage "2015s" @default.
• W1547840953 abstract "The basic cancer-related chemical and biological sciences, pathology, and epidemiology have contributed to the understanding that antimutagenesis and antiproliferation are the important general mechanisms of chemoprevention and to the development of antimutagenic and anti-proliferative agents as potential chemopreventive drugs. These disciplines have also provided the biochemical and histopathological bases for identifying intermediate biomarkers that can be used as surrogate end points for cancer incidence in clinical chemoprevention trials and for selecting cohorts for these trials. Particularly important as histological biomarkers of cancer are the cytonuclear morphological and densitometric changes that define intraepithelial neoplasia (IEN). IEN changes are on the causal pathway to cancer. They may serve as target lesions in Phase II chemoprevention trials and as standards against which other earlier cellular and molecular biomarkers can be evaluated. Strategies for the clinical evaluation of chemopreventive agents have been defined for seven targets--colorectal, prostate, lung, breast, bladder, oral, and cervical cancers. Cohorts have been identified for short-term Phase II trials that investigate the effects of chemopreventive agents on IEN and on earlier biomarkers. Patients with adenomas serve as a cohort for trials in colon. One cohort for Phase II trials in prostate is patients with early stage cancers scheduled for prostatectomy; another is patients with prostatic intraepithelial neoplasia (without prostatic carcinoma). Patients treated for lung cancer are at high risk for bronchial dysplasia and second cancers; such patients are a cohort for Phase II trials in lung cancer. Presurgical breast cancer patients and patients with ductal or lobular carcinoma in situ are cohorts for studies in breast. Patients with superficial bladder cancers (Ta/T1 with or without carcinoma in situ) are cohorts for studies of chemoprevention in bladder, and patients with dysplastic oral leukoplakia are evaluated for chemoprevention of oral cancers. Cervical intraepithelial neoplasia is a prototype IEN, and patients with cervical intraepithelial neoplasia are a cohort for studies of cervical cancer." @default.
• W1547840953 created "2016-06-24" @default.
• W1547840953 creator A5014024059 @default.
• W1547840953 creator A5014553553 @default.
• W1547840953 creator A5017000224 @default.
• W1547840953 creator A5025231476 @default.
• W1547840953 creator A5048308941 @default.
• W1547840953 creator A5059928711 @default.
• W1547840953 date "1994-04-01" @default.
• W1547840953 modified "2023-09-23" @default.
• W1547840953 title "Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials." @default.
• W1547840953 cites W1518290383 @default.
• W1547840953 cites W1522954291 @default.
• W1547840953 cites W1562872989 @default.
• W1547840953 cites W186393050 @default.
• W1547840953 cites W1889283847 @default.
• W1547840953 cites W1966165057 @default.
• W1547840953 cites W1966816499 @default.
• W1547840953 cites W1969391094 @default.
• W1547840953 cites W1973788738 @default.
• W1547840953 cites W197652651 @default.
• W1547840953 cites W1981444353 @default.
• W1547840953 cites W1986065869 @default.
• W1547840953 cites W2000330422 @default.
• W1547840953 cites W2001258296 @default.
• W1547840953 cites W2009042464 @default.
• W1547840953 cites W2010854729 @default.
• W1547840953 cites W2016089478 @default.
• W1547840953 cites W2021981163 @default.
• W1547840953 cites W2031949208 @default.
• W1547840953 cites W2034406569 @default.
• W1547840953 cites W2043539979 @default.
• W1547840953 cites W2049927041 @default.
• W1547840953 cites W2052408383 @default.
• W1547840953 cites W2053355503 @default.
• W1547840953 cites W2068094460 @default.
• W1547840953 cites W2084899200 @default.
• W1547840953 cites W2101392182 @default.
• W1547840953 cites W2109536804 @default.
• W1547840953 cites W2114418103 @default.
• W1547840953 cites W2118099369 @default.
• W1547840953 cites W2130163277 @default.
• W1547840953 cites W2145584839 @default.
• W1547840953 cites W2161888675 @default.
• W1547840953 cites W2163131487 @default.
• W1547840953 cites W2163819851 @default.
• W1547840953 cites W2167609773 @default.
• W1547840953 cites W2170251025 @default.
• W1547840953 cites W2170457937 @default.
• W1547840953 cites W2338198634 @default.
• W1547840953 cites W2339318589 @default.
• W1547840953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8137331" @default.
• W1547840953 hasPublicationYear "1994" @default.
• W1547840953 type Work @default.
• W1547840953 sameAs 1547840953 @default.
• W1547840953 citedByCount "52" @default.
• W1547840953 countsByYear W15478409532012 @default.
• W1547840953 countsByYear W15478409532013 @default.
• W1547840953 countsByYear W15478409532015 @default.
• W1547840953 countsByYear W15478409532016 @default.
• W1547840953 countsByYear W15478409532017 @default.
• W1547840953 crossrefType "journal-article" @default.
• W1547840953 hasAuthorship W1547840953A5014024059 @default.
• W1547840953 hasAuthorship W1547840953A5014553553 @default.
• W1547840953 hasAuthorship W1547840953A5017000224 @default.
• W1547840953 hasAuthorship W1547840953A5025231476 @default.
• W1547840953 hasAuthorship W1547840953A5048308941 @default.
• W1547840953 hasAuthorship W1547840953A5059928711 @default.
• W1547840953 hasConcept C121608353 @default.
• W1547840953 hasConcept C126322002 @default.
• W1547840953 hasConcept C142724271 @default.
• W1547840953 hasConcept C143998085 @default.
• W1547840953 hasConcept C2776235491 @default.
• W1547840953 hasConcept C2779534503 @default.
• W1547840953 hasConcept C2780192828 @default.
• W1547840953 hasConcept C2780234812 @default.
• W1547840953 hasConcept C530470458 @default.
• W1547840953 hasConcept C535046627 @default.
• W1547840953 hasConcept C71924100 @default.
• W1547840953 hasConcept C72563966 @default.
• W1547840953 hasConceptScore W1547840953C121608353 @default.
• W1547840953 hasConceptScore W1547840953C126322002 @default.
• W1547840953 hasConceptScore W1547840953C142724271 @default.
• W1547840953 hasConceptScore W1547840953C143998085 @default.
• W1547840953 hasConceptScore W1547840953C2776235491 @default.
• W1547840953 hasConceptScore W1547840953C2779534503 @default.
• W1547840953 hasConceptScore W1547840953C2780192828 @default.
• W1547840953 hasConceptScore W1547840953C2780234812 @default.
• W1547840953 hasConceptScore W1547840953C530470458 @default.
• W1547840953 hasConceptScore W1547840953C535046627 @default.
• W1547840953 hasConceptScore W1547840953C71924100 @default.
• W1547840953 hasConceptScore W1547840953C72563966 @default.
• W1547840953 hasIssue "7 Suppl" @default.
• W1547840953 hasLocation W15478409531 @default.
• W1547840953 hasOpenAccess W1547840953 @default.
• W1547840953 hasPrimaryLocation W15478409531 @default.
• W1547840953 hasRelatedWork W1588717771 @default.
• W1547840953 hasRelatedWork W1998677622 @default.

• next